Alx Oncology Holdings Inc (NASDAQ: ALXO) kicked off on Monday, up 12.16% from the previous trading day, before settling in for the closing price of $1.48. Over the past 52 weeks, ALXO has traded in a range of $1.19-$17.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -8.67%. While this was happening, its average annual earnings per share was recorded 26.31%. With a float of $34.33 million, this company’s outstanding shares have now reached $52.74 million.
The extent of productivity of a business whose workforce counts for 72 workers is very important to gauge. In terms of profitability, gross margin is 74.15%, operating margin of -6446.65%, and the pretax margin is -6095.12%.
Alx Oncology Holdings Inc (ALXO) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Alx Oncology Holdings Inc is 34.91%, while institutional ownership is 58.46%. The most recent insider transaction that took place on Aug 14 ’24, was worth 1,455. In this transaction SVP, FINANCE AND CAO of this company sold 564 shares at a rate of $2.58, taking the stock ownership to the 91,549 shares. Before that another transaction happened on Aug 14 ’24, when Company’s CHIEF MEDICAL OFFICER sold 1,365 for $2.58, making the entire transaction worth $3,522. This insider now owns 325,711 shares in total.
Alx Oncology Holdings Inc (ALXO) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.79 earnings per share (EPS), higher than consensus estimate (set at -0.84) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 26.31% per share during the next fiscal year.
Alx Oncology Holdings Inc (NASDAQ: ALXO) Trading Performance Indicators
Take a look at Alx Oncology Holdings Inc’s (ALXO) current performance indicators. Last quarter, stock had a quick ratio of 4.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.98, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.50 in one year’s time.
Technical Analysis of Alx Oncology Holdings Inc (ALXO)
The latest stats from [Alx Oncology Holdings Inc, ALXO] show that its last 5-days average volume of 0.78 million was inferior to 0.78 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 81.54%. Additionally, its Average True Range was 0.12.
During the past 100 days, Alx Oncology Holdings Inc’s (ALXO) raw stochastic average was set at 6.19%, which indicates a significant decrease from 94.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 85.81% in the past 14 days, which was lower than the 116.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5391, while its 200-day Moving Average is $7.3743. Now, the first resistance to watch is $1.7433. This is followed by the second major resistance level at $1.8267. The third major resistance level sits at $1.9633. If the price goes on to break the first support level at $1.5233, it is likely to go to the next support level at $1.3867. The third support level lies at $1.3033 if the price breaches the second support level.
Alx Oncology Holdings Inc (NASDAQ: ALXO) Key Stats
The company with the Market Capitalisation of 87.55 million has total of 52,743K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -160,810 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -30,710 K.
